BioLife Solutions Q2 revenue rises 21% to $28.5 million; Repligen deal pending
BioLife Solutions reported second-quarter 2026 revenue of $28.5 million, up 21% from a year earlier, and GAAP net income of $45.1 million, which includes a $42.4 million non-cash income tax benefit from the release of a valuation allowance. The company also disclosed a July 21, 2026 agreement under which Repligen will acquire BioLife for a total enterprise value of about $1.5 billion, after which BioLife will no longer be publicly traded, so shareholders' outcome depends on that deal closing.
Key points
- Q2 2026 revenue was $28.5 million, up $5.0 million or 21% from $23.4 million in Q2 2025 and up 4% from Q1 2026.
- GAAP net income was $45.1 million, or $0.92 per basic share, including the $42.4 million tax benefit; adjusted net income was $4.2 million.
- GAAP gross margin was 64% versus 65% a year earlier; adjusted EBITDA was $7.4 million, or 26% of revenue.
- Repligen will pay $11.25 in cash and 0.1442 Repligen shares per BioLife share; closing is expected in Q4 2026, subject to stockholder and regulatory approvals.
The filing
Written by AI on Nov 8, 2026, 2:07 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 06, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.